Pacira Biosciences (NASDAQ:PCRX) had its price target boosted by analysts at Jefferies Financial Group from $53.00 to $69.00 in a report released on Friday, The Fly reports. The firm presently has a "buy" rating on the stock. Jefferies Financial Group's target price indicates a potential upside of 19.96% from the stock's previous close.
Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Pacira Biosciences from a "buy" rating to a "hold" rating and set a $38.00 target price for the company. in a research report on Friday, March 27th. Stifel Nicolaus dropped their price target on Pacira Biosciences from $49.00 to $48.00 and set a "hold" rating on the stock in a research report on Thursday, May 7th. Royal Bank of Canada upped their price objective on Pacira Biosciences from $56.00 to $62.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 1st. Northland Securities upped their price target on shares of Pacira Biosciences from $50.00 to $54.00 and gave the stock a "market perform" rating in a research report on Tuesday, June 30th. Finally, Needham & Company LLC raised their price target on shares of Pacira Biosciences from $52.00 to $64.00 and gave the company a "buy" rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Pacira Biosciences currently has an average rating of "Buy" and a consensus target price of $57.40.
Shares of Pacira Biosciences stock opened at $57.52 on Friday. The company has a current ratio of 5.37, a quick ratio of 4.63 and a debt-to-equity ratio of 0.94. Pacira Biosciences has a twelve month low of $27.46 and a twelve month high of $58.19. The business's fifty day moving average price is $46.55 and its 200 day moving average price is $42.40. The stock has a market capitalization of $2.38 billion, a P/E ratio of -2,874.56, a PEG ratio of 2.73 and a beta of 1.31.
Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.23. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The firm had revenue of $105.68 million for the quarter, compared to the consensus estimate of $101.64 million. During the same quarter in the previous year, the firm posted $0.22 EPS. The firm's quarterly revenue was up 15.7% on a year-over-year basis. As a group, sell-side analysts predict that Pacira Biosciences will post 0.99 EPS for the current year.
In other news, SVP Charles Anthony Laranjeira sold 60,101 shares of the company's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $50.27, for a total value of $3,021,277.27. Following the transaction, the senior vice president now directly owns 27,851 shares of the company's stock, valued at $1,400,069.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lauren Bullaro Riker sold 2,000 shares of Pacira Biosciences stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $42.81, for a total value of $85,620.00. Following the sale, the vice president now directly owns 12,464 shares of the company's stock, valued at approximately $533,583.84. The disclosure for this sale can be found here. Insiders sold a total of 109,184 shares of company stock valued at $5,337,870 in the last ninety days. Company insiders own 5.80% of the company's stock.
Several institutional investors and hedge funds have recently bought and sold shares of PCRX. Renaissance Technologies LLC lifted its holdings in shares of Pacira Biosciences by 47.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,797,338 shares of the company's stock valued at $81,419,000 after buying an additional 582,238 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Pacira Biosciences by 1.8% in the first quarter. Baillie Gifford & Co. now owns 1,411,892 shares of the company's stock valued at $47,341,000 after acquiring an additional 24,447 shares during the last quarter. State Street Corp grew its position in Pacira Biosciences by 5.6% in the first quarter. State Street Corp now owns 1,403,659 shares of the company's stock worth $47,065,000 after acquiring an additional 74,009 shares in the last quarter. Spyglass Capital Management LLC increased its stake in shares of Pacira Biosciences by 38.9% during the 1st quarter. Spyglass Capital Management LLC now owns 1,190,537 shares of the company's stock worth $39,919,000 after purchasing an additional 333,710 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its stake in shares of Pacira Biosciences by 43.9% in the 1st quarter. Loomis Sayles & Co. L P now owns 754,996 shares of the company's stock valued at $25,315,000 after purchasing an additional 230,403 shares during the last quarter.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
See Also: High-Yield Dividend Stocks
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
10 Rock-Solid Dividend Paying Stocks to Own
Historically low interest rates have made it difficult over the last decade for income-oriented investors that want to generate safe cash flow for their retirements.
Dividend-paying stocks have become more appealing to income investors because of their competitive yields, the favorite tax treatment that dividends receive and their ability to grow their payouts over time. While fixed interest rates from bond investments will lose purchasing power to inflation over time, the purchasing power of income from dividend growth stocks is more protected because companies tend raise their dividend payments every year.
In this slideshow, we look at ten of the best high-dividend stocks that offer strong yields (above 3.5%), have consistent cashflow and a strong track record of dividend growth. The companies in this slideshow have all raised their dividend every year for the last ten years.
These companies also have low payout ratios (below 75%), meaning that they will have the ability to continue to pay their dividend if their earnings have a temporary dip.
Stock prices will always fluctuate, but the dividends paid by these rock-solid dividend payers should remain secure with moderate earnings growth.
View the "10 Rock-Solid Dividend Paying Stocks to Own".